MedTrace Logo

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Austria

NCT01296425 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2017-12-26

No results posted yet for this study

Summary

This is a National, Multicentre, Observational Registry to study adherence and long term outcomes of therapy in paediatric subjects using Easypod™ electromechanical device for growth hormone treatment from hospitals in Austria and to assess the level of adherence of subjects receiving SAIZEN® via Easypod™.

Conditions

  • Growth Disorders

Interventions

DEVICE

Easypod™

Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™

Sponsors & Collaborators

  • Merck Gesellschaft mbH, Austria

    collaborator INDUSTRY

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Senior Medical Specialist · Merck Gesellschaft mbH, Austria

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Austria

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01296425 on ClinicalTrials.gov